Incorporation in polymeric nanocapsules improves the antioxidant effect of melatonin against lipid peroxidation in mice brain and liver

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 69, Issue 1, 2008, Pages 64-71

  Schaffazick, Scheila R ^a   Siqueira, Ionara R ^a   Badejo, Alessandra S ^a   Jornada, Denise S ^a   Pohlmann, Adriana R ^a   Netto, Carlos Alexandre ^a   Guterres, Sílvia S ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Brain; Lipid peroxidation; Liver; Melatonin; Polymeric nanocapsules; Total antioxidant reactivity

Indexed keywords

DICHLOROFLUORESCEIN; FREE RADICAL; LIPID; LUMINOL; MELATONIN; NANOCAPSULE; POLYSORBATE 80; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BRAIN; CHEMOLUMINESCENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; INJECTION; LIPID PEROXIDATION; LIVER; MALE; MOUSE; NONHUMAN;

ANIMALS; ANTIOXIDANTS; BRAIN; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; LIPID PEROXIDATION; LIVER; MALE; MELATONIN; MICE; MODELS, BIOLOGICAL; NANOCAPSULES; POLYMERS; TECHNOLOGY, PHARMACEUTICAL;

EID: 41549088846     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.11.010     Document Type: Article

References (67)

1. Barrenetxe J., Delagrange P., and Marti{dotless}́nez J.A. Physiological and metabolic functions of melatonin. J. Physiol. Biochem. 60 (2004) 61-72
2. Boutin J.A., Audinot V., Ferry G., and Delagrange P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol. Sci. 26 (2005) 412-419
3. Epstein F.H. Mechanisms of disease - melatonin in humans. N. Engl. J. Med. 336 (1997) 186-195
4. Hardeland R., Pandi-Perumal S.R., and Cardinali D.P. Molecules in focus. Int. J. Biochem. Cell Biol. 38 (2006) 313-316
5. Reiter R.J., Oh C.-S., and Fujimori O. Melatonin: its intracellular and genomic actions. Trends Endocrinol. Metab. 7 (1996) 22-27
6. Reiter R.J., Tang L., Garcia J.J., and Muñoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 60 (1997) 2255-2271
7. Reiter R.J. Oxidative damage in the cerebral nervous system: protection by melatonin. Prog. Neurobiol. 56 (1998) 359-384
8. Reiter R.J. Melatonin: clinical relevance. Best Pract. Res. Clin. Endocrinol. Metab. 17 (2003) 273-285
9. Karbownik M., Lewinski A., and Reiter R.J. Anticarcinogenic actions of melatonin which involve antioxidative process: comparison with other antioxidants. Int. J. Biochem. Cell Biol. 33 (2001) 735-753
10. Reiter R.J., Tan D.-X., and Burkhardt S. Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech. Ageing Dev. 123 (2002) 1007-1019
11. Cruz A., Padillo F.J., Torres E., Navarrete C.M., Muñoz-Castañeda J.R., Caballero F.J., Briceño J., Marchal T., Túnez I., Montilla P., Pera C., and Muntané J. Melatonin prevents experimental liver cirrhosis induced by thioacetamide in rats. J. Pineal Res. 39 (2005) 143-150
12. Guven A., Yavuz O., Cam M., Ercan F., Bukan N., Comunoglu C., and Gokce F. Effects of melatonin on streptozotocin-induced diabetic liver injury in rats. Acta Histochem. 108 (2006) 85-93
13. Wang H., Wei W., Wang N.-P., Gui S.-Y., Wu L., Sun W.-Y., and Xu S.-Y. Melatonin ameliorates carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress. Life Sci. 77 (2005) 1902-1915
14. Altun A., and Ugur-Altun B. Melatonin: therapeutic and clinic utilization. Int. J. Clin. Pract. 61 (2007) 835-845
15. Cheung R.T.F. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J. Pineal Res. 34 (2003) 153-160
16. Matsubara E., Shoji M., Murakami T., Kawarabayashi T., and Abe K. Alzheimer's disease and melatonin. Int. Congr. Ser. 1252 (2003) 395-398
17. Sahoo S.K., and Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today 8 (2003) 1112-1120
18. Garcia-Garcia E., Andrieux K., Gil S., and Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?. Int. J. Pharm. 298 (2005) 274-292
19. Schaffazick S.R., Guterres S.S., Lucca-Freitas L., and Pohlmann A.R. Caracterização e estabilidade fi{dotless}́sico-qui{dotless}́mica de sistemas poliméricos nanoparticulados para administração de fármacos. Quim. Nova 26 (2003) 726-737
20. Couvreur P., Barratt G., Fattal E., Legrand P., and Vauthier C. Nanocapsule technology: a review. Crit. Rev. Ther. Drug Carrier Syst. 19 (2002) 99-134
21. Teixeira M., Alonso M.J., Pinto M.M.M., and Barbosa C.M. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. Eur. J. Pharm. Biopharm. 59 (2005) 491-500
22. Allémann E., Leroux J.-C., and Gurny R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv. Drug Deliv. Rev. 34 (1998) 171-189
23. Guterres S.S., Muller C.R., Michalowski C.B., Pohlmann A.R., and Dalla Costa T. Gastro-intestinal tolerance following oral administration of spray-dried diclofenac-loaded nanocapsules and nanospheres. S.T.P. Pharma Sci. 11 (2001) 229-233
24. Schaffazick S.R., Pohlmann A.R., Dalla-Costa T., and Guterres S.S. Freeze-drying polymeric colloidal suspensions: nanocapsules, nanospheres and nanodispersion. A comparative study. Eur. J. Pharm. Biopharm. 56 (2003) 501-505
25. 10-loaded PMMA nanoparticles by a new emulsification process based on microfluidization. Colloids Surf. A Physicochem. Eng. Asp. 210 (2002) 95-104
26. Ratnam D.V., Ankola D.D., Bhardwaj V., Sahana D.K., and Ravi Kumar M.N.V. Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. J. Control. Release 113 (2006) 189-207
27. Bala I., Bhardwaj V., Hariharan S., Kharade S.V., Roy N., and Kumar M.N.V.R. Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J. Drug Target. 14 (2006) 27-34
28. Palumbo M., Russo A., Cardile V., Renis M., Paolino D., Puglisi G., and Fresta M. Improved antioxidant effect of idebenone-loaded polyethyl-2 cyanoacrylate nanocapsules tested on human fibroblasts. Pharm. Res. 19 (2002) 71-78
29. Schaffazick S.R., Pohlmann A.R., de Cordova C.A.S., Creczynski-Pasa T.B., and Guterres S.S. Protective properties of melatonin-loaded nanoparticles against lipid peroxidation. Int. J. Pharm. 289 (2005) 209-213
30. Shea T.B., Ortiz D., Nicolosi R.J., Kumar R., and Watterson A.C. Nanosphere-mediated delivery of vitamin E increases its efficacy against oxidative stress resulting from exposure to amyloid beta. J. Alzheimers Dis. 7 (2005) 297-301
31. Friese A., Seiller E., Quack G., Lorenz B., and Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49 (2000) 103-109
32. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. Int. Congr. Ser. 1277 (2005) 85-94
33. Schröder U., and Sabel B.A. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 710 (1996) 121-124
34. Kreuter J., Petrov V.E., Kharkevich D.A., and Alyautdin R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Control. Release 49 (1997) 81-87
35. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Ya., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 (1999) 1564-1569
36. Olivier J.-C., Fenart L., Chauvet R., Pariat C., Cecchelli R., and Couet W. Indirect evidence that drug brain targeting using polysorbate-80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16 (1999) 1836-1842
37. 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice. Life Sci. 66 (2000) 495-502
38. Gelperina S.E., Khalansky A.S., Skidan I.N., Smirnova Z.S., Bobruskin A.I., Severin S.E., Turowski B., Zanella F.E., and Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126 (2002) 131-141
39. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautdin R., von Briesen H., and Begley D.J. Direct Evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20 (2003) 409-416
40. Sun W., Xie C., Wang H., and Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 25 (2004) 3065-3071
41. Gao K., and Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. Pharm. 310 (2006) 213-219
42. Calvo P., Gouritin B., Chacun H., Desmaële D., D'Angelo J., Noel J.-P., Georgin D., Fatal E., Andreux J.P., and Couvreur P. Long-circulation PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18 (2001) 1157-1166
43. Garcia-Garcia E., Andrieux K., Gil S., Kim H.R., Doan T.L., Desmaële D., d'Angelo J., Taran F., Georgin D., and Couvreur P. A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int. J. Pharm. 298 (2005) 310-314
44. Schaffazick S.R., Pohlmann A.R., Mezzalira G., and Guterres S.S. Development of nanocapsule suspensions and nanocapsule spray-dried powders containing melatonin. J. Braz. Chem. Soc. 17 (2006) 562-569
45. Fessi H., Puisieux F., Devissaguet J.-P., Ammoury N., and Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55 (1989) r1-r4
46. Pohlmann A.R., Weiss V., Mertins O., Pesce da Silveira N., and Guterres S.S. Spray-dried indometacin-loaded polyester nanocapsules and nanospheres: development, stability evaluation and nanostructure models. Eur. J. Pharm. Sci. 16 (2002) 305-312
47. Buege J.A., and Aust S.D. Microssomal lipid peroxidation. Methods Enzymol. 52 (1978) 302-310
48. Siqueira I.R., Fochesatto C., da Silva Torres I.L., Dalmaz C., and Netto C.A. Aging affects oxidative state in hippocampus, hypothalamus and adrenal glands of Wistar rats. Life Sci. 78 (2005) 271-278
49. Lissi E., Pascual C., and del Castillo M.D. Luminol luminescence induced by 2,2′-Azo-bis(2-amidinopropane) thermolysis. Free Radic. Res. Commun. 17 (1992) 299-311
50. Lissi E., Salim-Hanna M., Pascual C., and del Castillo M.D. Evaluation of total antioxidant potential (TRAP) and total antioxidant reactivity from luminol-enhanced chemiluminescence measurements. Free Radic. Biol. Med. 18 (1995) 153-158
51. Driver A.S., Kodavanti P.R.S., and Mundy W.R. Age-related in reactive oxygen species production in rat brain homogenates. Neurotoxicol. Teratol. 22 (2000) 175-181
52. Sriram K., Pai K.S., Boyd M.R., and Ravindranath V. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res. 749 (1997) 44-52
53. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
54. Tröster S.D., Müller U., and Kreuter J. Modification on the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61 (1990) 85-100
55. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
56. Radwan M.A., Zaghloul I.Y., and Aly Z.H. In vivo performance of parenteral theophylline-loaded polyisobutylcyanoacrylate nanoparticles in rats. Eur. J. Pharm. Sci. 8 (1999) 95-98
57. Maincent P., Thouvenot P., Amicabile C., Hoffman M., Kreuter J., Couvreur P., and Devissaguet J.P. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm. Res. 9 (1992) 1534-1539
58. Baydas G., Kutlu S., Naziroglu M., Canpolat S., Sandal S., Ozcan M., and Kelestimur H. Inhibitory effects of melatonin on neural lipid peroxidation induced by intracerebroventricularly administered homocysteine. J. Pineal Res. 34 (2003) 36-39
59. Esparza J.L., Gómez M., Nogués M.R., Paternain L., Mallol J., and Domingo J.L. Melatonin reduces oxidative stress and increases gene expression in the cerebral cortex and cerebellum of aluminum-exposed rats. J. Pineal Res. 39 (2005) 129-136
60. Baydas G., and Tuzcu M. Protective effects of melatonin against ethanol-induced reactive gliosis in hippocampus and cortex of young and aged rats. Exp. Neurol. 194 (2005) 175-181
61. Baydas G., Yasar A., and Tuzcu M. Comparison of the impact of melatonin on chronic ethanol-induced learning and memory impairment between young and aged rats. J. Pineal Res. 39 (2005) 346-352
62. Acuña-Castroviejo D., Coto-Montes A., Monti M.G., Ortiz G.G., and Reiter R.J. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 60 (1997) 23-29
63. Carneiro R.C.G., and Reiter R.J. Melatonin protects against lipid peroxidation induced by δ-aminolevulinic acid in rat cerebellum, cortex and hippocampus. Neuroscience 82 (1998) 293-299
64. Rezzani R., Buffoli B., Rodella L., Stacchiotti A., and Bianchi R. Protective role of melatonin in cyclosporine A-induced oxidative stress in rat liver. Int. Immunopharmacol. 5 (2005) 1397-1405
65. Contuk G., Ercan F., Çetinel S., Çikler E., and Sener G. Role of melatonin in reducing water avoidance stress-induced degeneration of the liver. Dig. Dis. Sci. 50 (2005) 738-744
66. Túnez I., Muñoz M.C., Villavicencio M.A., Medina F.J., de Prado E.P., Espejo I., Barcos M., Salcedo M., Feijóo M., and Montilla P. Hepato- and neurotoxicity by thiocetamide: protective effects of melatonin and dimethylsulfoxide. Pharmacol. Res. 52 (2005) 223-228
67. Sigala F., Theocharis S., Sigalas K., Markantonis-Kyroudis S., Papalabros E., Triantafyllou A., Kostopanagiotou G., and Andreadou I. Therapeutic value of melatonin in an experimental model of liver injury and regeneration. J. Pineal Res. 40 (2006) 270-279